Bringing hope with life-changing therapies to patients & their families

We develop therapies for patients with rare diseases

●  ●

Our lead program, QLS-215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of Hereditary Angioedema (HAE)

LEARN MORE

March 11, 2021: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

March 2, 2021: Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

January 29, 2021: Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

Scroll to Top